Similar articles

• Empirical Therapy of Community-Acquired Pneumonia: Advancing Evidence or Just More Doubt?

  Mandell LA, Waterer GW. Mandell LA, et al. JAMA. 2015 Jul 28;314(4):396-7. doi: 10.1001/jama.2015.3858. JAMA. 2015. PMID: 26219057 No abstract available.
• β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial.

  Garin N, Genné D, Carballo S, Chuard C, Eich G, Hugli O, Lamy O, Nendaz M, Petignat PA, Perneger T, Rutschmann O, Seravalli L, Harbarth S, Perrier A. Garin N, et al. JAMA Intern Med. 2014 Dec;174(12):1894-901. doi: 10.1001/jamainternmed.2014.4887. JAMA Intern Med. 2014. PMID: 25286173 Clinical Trial.
• The clinical efficacy of fluoroquinolone and macrolide combination therapy compared with single-agent therapy against community-acquired pneumonia caused by Legionella pneumophila.

  Nakamura S, Yanagihara K, Izumikawa K, Seki M, Kakeya H, Yamamoto Y, Senjyu H, Saito A, Kohno S. Nakamura S, et al. J Infect. 2009 Sep;59(3):222-4. doi: 10.1016/j.jinf.2009.06.008. Epub 2009 Jun 21. J Infect. 2009. PMID: 19592113 No abstract available.
• Diagnosing and treating atypical pneumonia.

  Smith G, Hosker H. Smith G, et al. Practitioner. 2001 Sep;245(1626):736-40, 742, 746. Practitioner. 2001. PMID: 11584587 Review. No abstract available.
• The treatment of Legionnaires' disease.

  Dedicoat M, Venkatesan P. Dedicoat M, et al. J Antimicrob Chemother. 1999 Jun;43(6):747-52. doi: 10.1093/jac/43.6.747. J Antimicrob Chemother. 1999. PMID: 10404312 Review. No abstract available.